ReviewAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2015
Improving Clinical Trial Efficiency: Thinking outside the Box.
Review in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.American journal of hematology · 2018Trial
- Combined integrated protocol/basket trial design for a first-in-human trial.Orphanet journal of rare diseases · 2016Trial
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.Diabetes, obesity & metabolism · 2026Article
- Non-invasive multiple cancer screening using trained detection canines and artificial intelligence: a prospective double-blind study.Scientific reports · 2024Article
- Review
- High-Sensitivity Cardiac Troponin T and Cardiovascular Risk After Ischemic Stroke or Transient Ischemic Attack.JACC. Advances · 2024Article
- Application of radiomics in lung immuno-oncology.Precision radiation oncology · 2023Review
- Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.Orphanet journal of rare diseases · 2022Review
- Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders.Frontiers in pharmacology · 2022Article
- Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials.Life (Basel, Switzerland) · 2021Review
- Stratification of patients in NASH clinical trials: A pitfall for trial success.JHEP reports : innovation in hepatology · 2020Review
- Article
- Reporting of master protocols towards a standardized approach: A systematic review.Contemporary clinical trials communications · 2019Article
- Design and Endpoints of Clinical Trials, Current and Future.Digestive diseases and sciences · 2019Review
- Toward A Universal Biomedical Data Translator.Clinical and translational science · 2019Article
- Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies.Ecancermedicalscience · 2019Review
- Master protocol trials in oncology: Review and new trial designs.Contemporary clinical trials communications · 2018Article
- Clinical trial design and recommendations: collectively, we can take them.Clinical and experimental medicine · 2018Article
- Signature program: a platform of basket trials.Oncotarget · 2018Article
- Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Clinical trial design strategies have evolved over the past few years as a means to accelerate the drug development process so that the right therapies can be delivered to the right patients. Basket, umbrella, and adaptive enrichment strategies represent a class of novel designs for testing targeted therapeutics in oncology. Umbrella trials include a central infrastructure for screening and identification of patients, and focus on a single tumor type or histology with multiple subtrials, each testing a targeted therapy within a molecularly defined subset. Basket trial designs offer the possibility to include multiple molecularly defined subpopulations, often across histology or tumor types, but included in one cohesive design to evaluate the targeted therapy in question. Adaptive enrichment designs offer the potential to enrich for patients with a particular molecular feature that is predictive of benefit for the test treatment based on accumulating evidence from the trial. This review will aim to discuss the fundamentals of these design strategies, the underlying statistical framework, the logistical barriers of implementation, and, ultimately, the interpretation of the trial results. New statistical approaches, extensive multidisciplinary collaboration, and state of the art data capture technologies are needed to implement these strategies in practice. Logistical challenges to implementation arising from centralized assay testing, requirement of multiple specimens, multidisciplinary collaboration, and infrastructure requirements will also be discussed. This review will present these concepts in the context of the National Cancer Institute's precision medicine initiative trials: MATCH, ALCHEMIST, Lung MAP, as well as other trials such as FOCUS4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.